Keens T, Hoffman V, Topuria I, Elder K, Cerf S, Mulder K, Roberts J, Lysinger J, Del Carmen Reyes M, Berdella M, Cairns AM, Jain M, Ganapathy V, Lou Y, Morcos B, Wu C, Sass L, VX19-CFD-003 Study Group. Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis. Heliyon. 2024 Mar 26;10(7):e28508. doi: 10.1016/j.heliyon.2024.e28508
Lin HM, Davis KL, Kaye JA, Luptakova K, Nagar SP, Mohty M. Real-world treatment patterns, outcomes, and healthcare resource utilization in relapsed or refractory multiple myeloma: evidence from a medical record review in France. Adv Hematol. 2019 Jan 29;2019(4625787). doi: 10.1155/2019/4625787
Davis KL, Cote I, Kaye JA, Mendelson E, Gao H, Perez Ronco J. Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib. Adv Hematol. 2015 Oct;2015(2015):848473. doi: 10.1155/2015/848473
Brodtkorb T, Kogler GF, Arndt A. The influence of metatarsal support height and longitudinal axis position on plantar foot loading. Clin Biomech (Bristol, Avon). 2008;23(5):640-7.